Valproic acid and ethosuxamide both trump lamotrigine when treating childhood absence epilepsy
Monotherapy with valproic acid or ethosuxamide is better than lamotrigine for treating childhood absence epilepsy, a US study reports (New England Journal of Medicine 2010;362:790).
With roughly 150 children randomised to each treatment, 58%, 53% and 29% of patients were free from treatment failure after 16 weeks with valproic acid, ethosuxamide and lamotrigine, respectively (P<0.001 for both valproic acid vs lamotrigine and ethosuxamide vs lamotrigine).
Attentional dysfunction, a secondary outcome, was more common with valproic acid than ethosuxamide (P=0.03).
Citation: Clinical Pharmacist URI: 11004596
Recommended from Pharmaceutical Press